Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Amphotericin b liposomal may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for Amphotericin B SUN Pharma liposomal is an antifungal antibiotic. The active ingredient in Amphotericin B SUN Pharma liposomal is amphotericin B. Amphotericin B SUN Pharma liposomal is given as an infusion into a vein (a drip) in hospital by a doctor or nurse. Amphotericin B SUN Pharma liposomal has been studied in patients aged one month and above. Amphotericin B SUN Pharma liposomal is used to treat serious infections caused by fungi:
Amphotericin B SUN Pharma liposomal Before your first treatment Before your first treatment your doctor may give you a small amount of Amphotericin B SUN Pharma liposomal. They will then wait for approximately 30 minutes to see whether you have an allergic reaction, before continuing the infusion of the full dose. Your doctor will not give you Amphotericin B SUN Pharma liposomal
V002
threatening allergic reactions include: flushing, itching, sickness, swelling of the face, mouth, tongue and airways, often enough to cause difficulty breathing. Tell your doctor if any of these applies to you, you must not be given Amphotericin B SUN Pharma liposomal Warnings and precautions Your doctor will take special care with Amphotericin B SUN Pharma liposomal
V002
Tell your doctor if you are taking any of these medicines. Amphotericin B SUN Pharma liposomal may make any kidney damage caused by the medicine worse. If you are taking any of these medicines, your doctor or nurse will take regular blood samples to check your kidneys. Medicines that may lower your potassium levels
V002
Amphotericin B SUN Pharma liposomal contains soya oil. If you are allergic to peanut or soya, do not use this medicinal product.
Amphotericin B SUN Pharma liposomal Amphotericin B SUN Pharma liposomal is always given to you by a doctor or nurse. It is given into a vein (a drip). Amphotericin B SUN Pharma liposomal must not be given by any other method. To prepare the infusion Amphotericin B SUN Pharma liposomal must be dissolved in sterile water for injection and then diluted with a solution containing dextrose. Amphotericin B SUN Pharma liposomal must not be mixed with saline (salt) solutions or with other medicinal products or electrolytes. Amphotericin B SUN Pharma liposomal is not interchangeable with other amphotericin products. Before your first treatment Before your first treatment your doctor may give you a small amount of Amphotericin B SUN Pharma liposomal. They will then wait for approximately 30 minutes to see whether you have an allergic reaction, before continuing the infusion of the full dose. Use in adults and in elderly people Your dose of Amphotericin B SUN Pharma liposomal will depend on your body weight and your own particular needs. Fungal infections of one or more organs of the body Treatment is normally started at 1 mg per kg of body weight, every day over 2 to 4 weeks. Your doctor may decide to increase the amount you receive to as high as 3 mg per kg of body weight. For mucormycosis the starting dose is normally 5 mg per kg of body weight per day. The duration of therapy will be determined on an individual basis by your doctor. Suspected fungal infections in patients with a raised temperature and neutropenia Treatment is normally started at 1 mg per kg body weight, per day. Your doctor may decide to increase the amount you receive to as high as 3 mg per kg body weight. Visceral leishmaniasis The usual dose is 1 to 1.5 mg per kg body weight, per day for 21 days, or 3 mg per kg body weight for 10 days. If you have a severely weakened immune system (for instance, if you are HIV positive), the dose is 1 to 1.5 mg per kg body weight for 21 days. Due to the risk of re-infection, on-going treatment or a further course of treatment may be needed. Use in children Amphotericin B SUN Pharma liposomal has been used to treat children. The dose of Amphotericin B SUN Pharma liposomal for a child is calculated per kg of body weight in the same way as for adults. Amphotericin B SUN Pharma liposomal is not recommended in babies under 1 month old. Use in patients with kidney problems No change in dose or frequency of infusion is required. Your doctor or nurse will take regular blood samples to test for changes in kidney function during Amphotericin B SUN Pharma liposomal treatment. How long will the infusion take? Normally the infusion will take 30 to 60 minutes. For doses greater than 5 mg per kg of body weight per day, the infusion could take up to 2 hours. If you receive a higher dose of Amphotericin B SUN Pharma liposomal than you should
V002
You should tell your doctor immediately if you think you received too much Amphotericin B SUN Pharma liposomal. If you have any further questions on the use of this product, ask your doctor. 4. Possible side effects Like all medicines, this medicine can cause side effects, although not everybody gets them. Tell your doctor immediately if you have a severe allergic reaction, chest pain, develop an irregular heart beat or kidney problems (signs include tiredness and passing less urine). Severe allergic reaction side effects may include: skin rash, difficulty breathing, wheezing, chest tightness, swelling of the airways/tongue/face/hands or feet, loss of consciousness, confusion or dizziness, rapid or irregular heart beat, vomiting and nausea.
during the infusion You may get side effects during the infusion: Very common (may affect more than 1 in 10 people)
V002
–
back pain abnormal results for liver or kidney function showing up in blood tests or urine tests. high blood potassium levels
Uncommon side effects (may affect up to 1 in 100 people)
Amphotericin B SUN Pharma liposomal Amphotericin B SUN Pharma liposomal is stored in the pharmacy. Keep this medicine out of the sight and reach of children. Do not use Amphotericin B SUN Pharma liposomal after the date which is stated on the label after {EXP}. The expiry date refers to the last day of the month. This product does not require any special storage condition. Do not store partially used vials for future patient use. Amphotericin B SUN Pharma liposomal is a single dose, unpreserved, sterile, freeze-dried yellow powder to be dissolved in water for injection and diluted with a dextrose solution before infusion into a vein. From a microbiological point of view, the product should be used immediately once dissolved and diluted. If it is not used immediately, in-use storage times and conditions prior to use are the responsibility of the doctor or pharmacist and would normally not be longer than 24 hours at 2°C to 8°C unless reconstitution (dissolving the powder in water for injection) and dilution have taken place in controlled conditions to prevent microbial contamination. Where reconstitution (dissolving the powder in water for injection) and dilution with dextrose solution are carried out under controlled conditions the storage time varies depending on the concentration of dextrose used and the storage temperature. Please refer to the Summary of Product Characteristics for further information. Do not use Amphotericin B SUN Pharma liposomal if there is any evidence of deterioration or foreign matter.
V002
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.
What Amphotericin B SUN Pharma liposomal contains
V002
Do NOT mix Amphotericin B SUN Pharma liposomal with other drugs or electrolytes. Aseptic technique must be observed in all handling, since no preservative or bacteriostatic agent is present in Amphotericin B SUN Pharma liposomal, or in the material specified for reconstitution and dilution. Vials of Amphotericin B SUN Pharma liposomal containing 50 mg of Amphotericin B are prepared as follows:
IMMEDIATELY after the addition of water, SHAKE THE VIAL VIGOROUSLY for 30 seconds to completely disperse the Amphotericin B SUN Pharma liposomal. After reconstitution the concentrate is a translucent, yellow dispersion. Visually inspect the vial for particulate matter and continue shaking until complete dispersion is obtained. Do not use if there is evidence of precipitation of foreign matter.
–
Calculate the amount of reconstituted Amphotericin B SUN Pharma liposomal (4 mg/ml) to be further diluted (see table below).
–
The infusion solution is obtained by dilution of the reconstituted Amphotericin B SUN Pharma liposomal with between one (1) and nineteen (19) parts dextrose solution (5%, 10% or 20%) for infusion by volume, to give a final concentration in the recommended range of 2.00mg/ml to 0.20mg/ml amphotericin B as Amphotericin B SUN Pharma liposomal (see table below).
–
Withdraw the calculated volume of reconstituted Amphotericin B SUN Pharma liposomal into a sterile syringe. Using the 5-micron filter provided, instill the Amphotericin B SUN Pharma liposomal preparation into a sterile container with the correct amount of Dextrose solution (5%, 10% or 20%) for infusion.
An in-line membrane filter may be used for intravenous infusion of Amphotericin B SUN Pharma liposomal. However, the mean pore diameter of the filter should not be less than 1.0 micron. Preparation of Amphotericin B SUN Pharma liposomal for Infusion An example is provided in the table below of the preparation of Amphotericin B SUN Pharma liposomal dispersion for infusion at a dose of 3mg/kg/day in dextrose 5% solution for infusion. Note that this table relates to doses of 3mg/kg/day only, however other doses than this may be prescribed for a patient. If a dose other than 3mg/kg/day has been prescribed for a patient, then the appropriate calculations must be undertaken and the table cannot be used. Example of the preparation of Amphotericin B SUN Pharma liposomal solution for infusion at a dose of 3mg/kg/day in dextrose 5% solution for infusion Weight (kg)
V002
Number of vials
Amount Amphotericin B SUN Pharma liposomal (mg) to be withdrawn for further dilution
Volume of reconstituted Amphotericin B SUN Pharma liposomal (ml)*
To make up a 0.2 mg/ml concentration (1 in 20 dilution)
To make up a 2.0 mg/ml concentration (1 in 2 dilution)
Volume of 5% dextrose needed (ml)
Volume of 5% dextrose needed (ml)
Total volume (ml; Amphotericin B SUN Pharma liposomal plus 5% dextrose)
Total volume (ml; Amphotericin B SUN Pharma liposomal plus 5% dextrose)
10 25 40 55 70 85
1 30 7.5 142.5 150 7.5 15 2 75 18.75 356.25 375 18.75 37.5 3 120 30 570 600 30 60 4 165 41.25 783.75 825 41.25 82.5 5 210 52.5 997.5 1050 52.5 105 6 255 63.75 1211.25 1275 63.75 127.5
For single use only. Discard any unused contents. Any unused product or waste material should be disposed of in accordance with local requirements.
V002
Amphotericin B SUN Pharma liposomal 50 mg powder for dispersion for infusion comes as infusion containing 50mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Amphotericin B SUN Pharma liposomal 50 mg powder for dispersion for infusion is amphotericin b liposomal.
This leaflet reproduces the patient information leaflet approved for Amphotericin B SUN Pharma liposomal 50 mg powder for dispersion for infusion, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Amphotericin B SUN Pharma liposomal is indicated in adults and children aged 1 month to 18 years old for:
• the treatment of severe systemic and/or deep mycoses
• the treatment of visceral leishmaniasis in immunocompetent patients including both adults and children
• the empirical treatment of presumed fungal infections in febrile neutropenic patients, where the fever has failed to respond to broad spectrum antibiotics and appropriate investigations have failed to define a bacterial or viral cause.
Infections successfully treated with Amphotericin B SUN Pharma liposomal include: disseminated candidiasis, aspergillosis, mucormycosis, chronic mycetoma, cryptococcal meningitis and visceral leishmaniasis.
Amphotericin B SUN Pharma liposomal should not be used to treat the common clinically inapparent forms of fungal disease which show only positive skin or serologic tests.
Non-equivalence of amphotericin products
Different amphotericin products (sodium deoxycholate, liposomal, lipid complex) are not equivalent in terms of pharmacodynamics, pharmacokinetics and dosing and so the products should not be used interchangeably without accounting for these differences. Both the trade name, common name and dose should be verified pre-administration.
There is a risk of under-dose if Amphotericin B SUN Pharma liposomal is administered at a dose recommended for amphotericin B deoxycholate.
Posology
Anaphylaxis and anaphylactoid reactions can occur at any point of treatment of Amphotericin B SUN Pharma liposomal therefore the patient should be monitored closely during every treatment of Amphotericin B SUN Pharma liposomal (see section 4.4).
Treatment of mycoses
Therapy is usually instituted at a daily dose of 3 to 5 mg/kg of body weight for a minimum of 14 days. Dosage of amphotericin B as Amphotericin B SUN Pharma liposomal must be adjusted to the specific requirements of each patient.
Mucormycosis
For suspected or confirmed infection, the recommended starting dose is 5 to 10 mg/kg/day.
In patients with brain involvement or solid-organ transplant, dose at 10 mg/kg/day. Avoid slow escalation of doses. The duration of therapy should be determined on an individual basis. Courses of up to 6 – 8 weeks are commonly used in clinical practice; longer durations of therapy may be required for deep seated infections or in cases of prolonged courses of chemotherapy or neutropenia.
Although doses greater than 5 mg/kg and up to a maximum of 10 mg/kg have been used in clinical trials and clinical practice, data on the safety and efficacy of Amphotericin B SUN Pharma liposomal for the treatment of mucormycosis at these higher doses are limited. Therefore, a benefit:risk assessment should be made on an individual patient level to determine whether the potential benefits of treatment are considered to outweigh the known increased risk of toxicity at higher Amphotericin B SUN Pharma liposomal doses (see section 4.4).
HIV associated Cryptococcal meningitis
Administer a single dose of 10 mg/kg Amphotericin B SUN Pharma liposomal on day 1, in combination with daily flucytosine 100 mg/kg and daily fluconazole 1200 mg, both administered for 14 days.
After the 2-week induction period, patients should receive fluconazole 800 mg daily for 8 weeks and then at a dose of 200 mg daily thereafter at the treating physician's discretion.
Treatment of visceral leishmaniasis
A total dose of 21.0 - 30.0 mg/kg of body weight given over 10-21 days may be used in the treatment of visceral leishmaniasis. Particulars as to the optimal dosage and the eventual development of resistance are as yet incomplete. The product should be administered under strict medical supervision.
Empirical treatment of febrile neutropenia
The recommended daily dose is 3 to 5 mg/kg body weight per day. Treatment should be continued until the recorded temperature is normalised for 3 consecutive days. In any event, treatment should be discontinued after a maximum of 42 days.
Paediatric population
Both systemic fungal infections in children and presumed fungal infections in children with febrile neutropenia have been successfully treated with Amphotericin B SUN Pharma liposomal, without reports of unusual adverse events. Amphotericin B SUN Pharma liposomal has been studied in paediatric patients aged one month to 18 years old. Doses used in these clinical studies were the same as those used in adults on a mg/kg body weight basis.
Amphotericin B SUN Pharma liposomal is not recommended for use in children below 1 month old due to lack of data on safety and efficacy.
Elderly patients
No alteration in dose or frequency of dosing is required.
Renal impairment
Amphotericin B SUN Pharma liposomal has been administered to a large number of patients with pre-existing renal impairment at starting doses ranging from 1-3 mg/kg/day in clinical trials and no adjustment in dose or frequency of administration was required (See section 4.4).
Hepatic impairment
No data are available on which to make a dose recommendation for patients with hepatic impairment (See section 4.4).
Method of administration
Amphotericin B SUN Pharma liposomal should be administered by intravenous infusion over a 30 - 60 minute period and the patient closely observed. For doses greater than 5mg/kg/day, intravenous infusion over a 2 hour period is recommended (see section 4.4). The recommended concentration for intravenous infusion is 0.20 mg/ml to 2.00 mg/ml amphotericin B as Amphotericin B SUN Pharma liposomal.
For instructions on reconstitution and dilution of the product before administration, see section 6.6.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 unless, in the opinion of the physician, the condition requiring treatment is life-threatening and amenable only to Amphotericin B SUN Pharma liposomal therapy.
Anaphylaxis and anaphylactoid reactions
Anaphylaxis and anaphylactoid reactions have been reported in association with Amphotericin B SUN Pharma liposomal infusion. Allergic type reactions, including severe infusion-related reactions can occur during administration of amphotericin-containing products, including Amphotericin B SUN Pharma liposomal (see section 4.8). Therefore, every dose of Amphotericin B SUN Pharma liposomal should be infused over 30-60 minutes and the patient closely monitored every time. If a severe allergic or anaphylactic/anaphylactoid reaction occurs, the infusion should be immediately discontinued and the patient should not receive further infusion of Amphotericin B SUN Pharma liposomal.
Infusion-related reactions
Other severe infusion-related reactions can occur during administration of amphotericin B- containing products, including Amphotericin B SUN Pharma liposomal (see section 4.8). Although infusion-related reactions are not usually serious, consideration of precautionary measures for the prevention or treatment of these reactions should be given to patients who receive Amphotericin B SUN Pharma liposomal therapy. Slower infusion rates (over 2 hours) or routine doses of diphenhydramine, paracetamol, pethidine and/or hydrocortisone have been reported as successful in their prevention or treatment.
Renal toxicity
Amphotericin B SUN Pharma liposomal has been shown to be substantially less toxic than conventional amphotericin B, particularly with respect to nephrotoxicity; however, renal adverse reactions may still occur.
In studies comparing Amphotericin B SUN Pharma liposomal 3 mg/kg daily with higher doses (5, 6 or 10 mg/kg daily), it was found that the incidence rates of increased serum creatinine, hypokalaemia and hypomagnesaemia were notably higher in the high dose groups.
In particular, caution should be exercised when prolonged therapy is required. Regular laboratory evaluation of serum electrolytes, particularly potassium and magnesium as well as renal, hepatic and haematopoietic function should be performed, at least once weekly. Renal function should be closely monitored in these patients. Due to the risk of hypokalaemia, appropriate potassium supplementation may be required during the course of Amphotericin B SUN Pharma liposomal administration. If clinically significant reduction in renal function or worsening of other parameters occurs, consideration should be given to dose reduction, treatment interruption or discontinuation. Cases of hyperkalaemia (some of them leading to cardiac arrhythmias and cardiac arrest) have been reported. Most of them occurred in patients with renal impairment, and some cases after potassium supplementation in patients with previous hypokalaemia. Therefore, renal function and laboratory evaluation of potassium, should be measured before and during treatment. This is particularly important in patients with pre-existing renal disease, who have already experienced renal failure, or in patients receiving concomitant nephrotoxic medications (see section 4.5).
Pulmonary toxicity
Acute pulmonary toxicity has been reported in patients given amphotericin B (as sodium deoxycholate complex) during or shortly after leukocyte transfusions. It is recommended that these infusions are separated by as long a period as possible and pulmonary function should be monitored.
Diabetic patients
Amphotericin B SUN Pharma liposomal contains approximately 900 mg of sucrose in each vial. This should be taken into account when treating diabetic patients.
Excipients
This medicinal product contains less than 1 mmol sodium (23 mg) per 50 mg vial, i.e. essentially 'sodium free'.
No specific interaction studies have been performed with Amphotericin B SUN Pharma liposomal. However, the following medicinal products are known to interact with amphotericin B and may interact with Amphotericin B SUN Pharma liposomal:
Nephrotoxic medications
Concurrent administration of Amphotericin B SUN Pharma liposomal with other nephrotoxic agents (for example ciclosporin, aminoglycosides, polymixins, tacrolimus and pentamidine) may enhance the potential for drug-induced renal toxicity in some patients.
However, in patients receiving concomitant ciclosporin and/or aminoglycosides, Amphotericin B SUN liposomal Pharma was associated with significantly less nephrotoxicity compared to amphotericin B. Regular monitoring of renal function is recommended in patients receiving Amphotericin B SUN Pharma liposomal with any nephrotoxic medications.
Corticosteroids, corticotropin (ACTH) and diuretics
Concurrent use of corticosteroids, ACTH and diuretics (loop and thiazide) may potentiate hypokalemia.
Digitalis glycosides
Amphotericin B SUN Pharma liposomal-induced hypokalemia may potentiate digitalis toxicity.
Skeletal muscle relaxants
Amphotericin B SUN Pharma liposomal-induced hypokalemia may enhance the curariform effect of skeletal muscle relaxants (e.g. tubocurarine).
Antifungals
Whilst synergy between amphotericin and flucytosine has been reported, concurrent use may increase the toxicity of flucytosine by possibly increasing its cellular uptake and/or impairing its renal excretion, therefore a benefit:risk assessment should be made on an individual patient level.
Antineoplastic agents
Concurrent use of antineoplastic agents may enhance the potential for renal toxicity, bronchospasm and hypotension.
Antineoplastic agents should be given concomitantly with caution.
Leukocyte transfusions
Acute pulmonary toxicity has been reported in patients given amphotericin B (as sodium deoxycholate complex) during or shortly after leukocyte transfusions. It is recommended these infusions are separated by as long a period as possible
and pulmonary function should be monitored.
Fertility
Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3).
Pregnancy
The safety of Amphotericin B SUN Pharma liposomal in pregnant women has not been established.
Systemic fungal infections have been successfully treated in pregnant women with conventional amphotericin B without obvious effect on the fetus, but the number of cases reported is insufficient to draw any conclusions on the safety of Amphotericin B SUN Pharma liposomal in pregnancy.
Amphotericin B SUN Pharma liposomal should only be used during pregnancy if the possible benefits to be derived outweigh the potential risks to the mother and fetus.
Breast-feeding
It is unknown whether Amphotericin B SUN Pharma liposomal is excreted in human breast milk. A decision on whether to breastfeed while receiving Amphotericin B SUN Pharma liposomal should take into account the potential risk to the child as well as the benefit of breast feeding for the child and the benefit of Amphotericin B SUN Pharma liposomal therapy for the mother.
No studies on the effects on the ability to drive and use machines have been performed. Some of the undesirable effects of Amphotericin B SUN Pharma liposomal presented below may impact the ability to drive and use machines.
Summary of adverse reactions
The following adverse reactions have been attributed to Amphotericin B SUN Pharma liposomal based on clinical trial data and post-marketing experience. The frequency is based on analysis from pooled clinical trials of 688 Amphotericin B SUN Pharma liposomal treated patients; the frequency of adverse reactions identified from post-marketing experience is not known. Adverse reactions are listed below by body system organ class using MedDRA and are sorted by frequency. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
Frequencies are defined as:
Very common
(≥ 1/10)
Common
(≥ 1/100 to < 1/10)
Uncommon
(≥ 1/1,000 to < 1/100)
Very rare
(<1/10,000),
Not known (cannot be estimated from the available data)
Blood and lymphatic system disorders
Uncommon: thrombocytopenia
Not known: anaemia
Immune system disorders
Uncommon: anaphylactoid reaction
Not known: anaphylactic reactions, hypersensitivity
Metabolism and nutrition disorders
Very common: hypokalaemia
Common: hyponatraemia, hypocalcaemia, hypomagnesaemia, hyperglycaemia, hyperkalaemia
Nervous system disorders
Common: headache
Uncommon: convulsion
Cardiac disorders
Common: tachycardia
Not known: cardiac arrest, arrhythmia
Vascular disorders
Common: hypotension, vasodilatation, flushing
Respiratory, thoracic and mediastinal disorders
Common: dyspnoea
Uncommon: bronchospasm
Gastrointestinal disorders
Very common: nausea, vomiting
Common: diarrhoea, abdominal pain
Hepatobiliary disorders
Common: abnormal liver function tests, hyperbilirubinaemia, increased alkaline phosphatase
Skin and subcutaneous disorders
Common: rash
Not known: angioneurotic oedema
Musculoskeletal and connective tissue disorders
Common: back pain
Not Known: rhabdomyolysis (associated with hypokalaemia), musculoskeletal pain (described as arthralgia or bone pain)
Renal and urinary disorders
Common: increased creatinine, increased blood urea
Not known: renal failure, renal insufficiency
General disorders and administration site conditions
Very Common: rigors, pyrexia,
Common: chest pain
Description of selected adverse reactions
Infusion-related reactions
Fever and chills/rigors are the most frequent infusion-related reactions expected to occur during Amphotericin B SUN Pharma liposomal administration. Less frequent infusion-related reactions may consist of one or more of the following symptoms: chest tightness or pain, dyspnoea, bronchospasm, flushing, tachycardia, hypotension and musculoskeletal pain (described as arthralgia, back pain, or bone pain). These resolve rapidly on stopping the infusion and may not occur with every subsequent dose or when slower infusion rates (over 2 hours) are used. In addition, infusion-related reactions may also be prevented by the use of premedication. However, severe infusion-related reactions may necessitate the permanent discontinuation of Amphotericin B SUN Pharma liposomal (see section 4.4).
In two double-blind, comparative studies, Amphotericin B SUN Pharma liposomal treated patients experienced a significantly lower incidence of infusion-related reactions, as compared to patients treated with conventional amphotericin B or amphotericin B lipid complex.
In pooled study data from randomised, controlled clinical trials comparing Amphotericin B SUN Pharma liposomal with conventional amphotericin B therapy in greater than 1,000 patients, reported adverse reactions were considerably less severe and less frequent in Amphotericin B SUN Pharma liposomal treated patients as compared with conventional amphotericin B treated patients.
A randomized phase III study assessed a single 10 mg/kg dose of Amphotericin B SUN Pharma liposomal with a backbone of 14 days flucytosine and fluconazole, compared to the control group (1-week conventional amphotericin B plus flucytosine followed by 1 week of fluconazole) in the treatment of HIV associated cryptococcal meningitis. The Amphotericin B SUN Pharma liposomal treated patients experienced fewer grade 3 or 4 adverse events compared to the control group. The safety profile observed in this patient population was consistent with the overall safety profile for Amphotericin B SUN Pharma liposomal.
Renal toxicity
Nephrotoxicity occurs to some degree with conventional amphotericin B in most patients receiving the product intravenously. In a double-blind study involving 687 patients, the incidence of nephrotoxicity with Amphotericin B SUN Pharma liposomal (as measured by serum creatinine increase greater than 2.0 times baseline measurement), was approximately half that for conventional amphotericin B. In another double-blind study involving 244 patients, the incidence of nephrotoxicity with Amphotericin B SUN Pharma liposomal (as measured by serum creatinine increase greater than 2.0 times baseline measurement) was approximately half that for Amphotericin B lipid complex.
Interference with Phosphorus Chemistry Assay
False elevations of serum phosphate may occur when samples from patients receiving Amphotericin B SUN Pharma liposomal are analyzed using the PHOSm assay (e.g. used in Beckman Coulter analyzers including the Synchron LX20). This assay is intended for the quantitative determination of inorganic phosphorus in human serum, plasma or urine samples.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
The toxicity of Amphotericin B SUN Pharma liposomal due to acute overdose has not been defined. If overdose should occur, cease administration immediately. Carefully monitor clinical status including renal and hepatic function, serum electrolytes and haematological status. Haemodialysis or peritoneal dialysis does not appear to affect the elimination of Amphotericin B SUN Pharma liposomal.
Special populations (including paediatric population):
No additional information is available in special populations.
Medicines sold in Romania with the same active substance: Cunoscut în România ca
⚠ Not the same combination. This medicine contains Amphotericin b liposomal. The products below do not contain exactly the same set of active substances — they are not direct substitutes.
Some of these do not contain exactly the same active substances — check each one. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →
Medicines sold in Poland with the same active substance: W Polsce znany jako
⚠ Not the same combination. This medicine contains Amphotericin b liposomal. The products below do not contain exactly the same set of active substances — they are not direct substitutes.
Some of these do not contain exactly the same active substances — check each one. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →
Ask anything about Amphotericin B SUN Pharma liposomal 50 mg powder for dispersion for infusion. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.